Salmonella is the leading cause of typhoidal and non-typhoidal infections in the world. The entry of Salmonella into the bloodstream causes an invasive disease state, resulting to high morbidity and mortality rates, especially in children. Owing to the misuse of antibiotics, certain Salmonella serovars are multi-drug resistant and do not respond to traditional antibiotics, such as ampicillin and trimethoprim-sulphamethoxazole, presenting a significant challenge for healthcare practitioners in treating and controlling the spread of this disease. Therefore, expensive third-generation cephalosporins, such as ceftriaxone, are currently used to treat Salmonella infection. However, a novel serovar of Salmonella that resists ceftriaxone was recently identified in Saudi Arabia, indicating wide spread Salmonella resistance. A comprehensive literature review on ceftriaxone resistance in Salmonella is therefore necessary to reflect upon current challenges. In this report, we provide a summary of Salmonella incidence, mechanisms of ceftriaxone resistance in Salmonella, and current treatment options.

沙门氏菌是世界上伤寒和非伤寒感染的主要原因。的进入沙门氏菌进入血液引起的侵袭性疾病状态，导致高发病率和死亡率，尤其是儿童。由于滥用抗生素，某些沙门氏菌血清多药耐药，对氨苄青霉素和甲氧苄氨嘧啶-甲氧恶唑等传统抗生素没有反应，这对医护人员在治疗和控制这种疾病的传播方面提出了重大挑战。因此，昂贵的第三代头孢菌素，例如头孢曲松，目前被用于治疗沙门氏菌感染。然而，沙门氏菌的新型血清最近在沙特阿拉伯发现了抗头孢曲松的药物，表明沙门氏菌耐药性广泛传播。因此，有必要对沙门氏菌中的头孢曲松耐药性进行全面的文献综述，以反映当前的挑战。在这份报告中，我们提供的摘要沙门氏菌发病，以头孢曲松耐药机制的沙门氏菌，并且目前的治疗方案。